Early response biomarker study for breast cancer treatment
Part of Cancer, Skin clinical trials.
This study looks at how breast cancer cells change during chemotherapy and immunotherapy before surgery. By analyzing tumor samples taken during treatment, doctors hope to find early signs of whether the treatment is working, which could lead to better-personalized care for people with triple negative or high-risk luminal breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older
- Your breast cancer must be either triple negative (no estrogen, progesterone, or HER2 receptors) or a high-risk luminal type (estrogen receptor positive, no HER2, but with aggressive features)
- You must be scheduled to receive chemotherapy and/or immunotherapy before surgery (neoadjuvant treatment)
- Your cancer must be early stage — it should not have spread beyond the breast or nearby lymph nodes
- You must be able to provide a tissue sample (biopsy) during treatment for research purposes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study takes small samples of your breast tumor tissue after (or during) treatment and grows them in lab animals to better study breast cancer. It may help researchers test future ideas for treating aggressive breast cancer types like triple-negative or Luminal B.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.